NeXeption, LLC is a biopharmaceutical management company that brings together product opportunities, management expertise and the necessary funding to reach compelling partnership milestones. The NeXeption management team has a proven track record in raising capital, operating development stage companies and forming strategic partnerships to advance products for the benefit of patients.


JANUARY 23, 2015
Alexar Awarded Michael J. Fox Foundation Grant for Research on a Novel Parkinson’s Disease Therapeutic

JANUARY 2, 2014
NeXeption, LLC Forms New Company Alexar Therapeutics, Inc. to Develop Novel LXR Agonist Portfolio for Dermatologic Indications; Raises $21.5 Million in Series A Financing

Dave Pfeiffer Named Alexar Chief Executive Officer

OCTOBER 2, 2014
Aclaris Therapeutics Closes $21 Million Series B Financing

JUNE 30, 2014
Aclaris Therapeutics Announces Positive Results from Phase 2 Clinical Trial of A-101 for the Removal of Seborrheic Keratosis, a Common Type of Skin Tumor